Article

Fatty Acids, Vitamin E Ease PMS Symptoms

Treatment with a capsule containing numerous polyunsaturated acids and vitamin E eased symptoms of PMS for as many as six months in a Brazilian trial.

A pill containing a mix of essential oils has been shown to significantly reduce the symptoms of premenstrual syndrome (PMS). Researchers writing in Reproductive Health tested the tablets by carrying out a randomized, controlled trial in 120 women.

Edilberto Rocha Filho worked with a team of researchers from the Federal University of Pernambuco, Brazil, to conduct the tests. He said, "The administration of 1 or 2 grams of essential fatty acids to patients with PMS resulted in a significant decrease in symptom scores. Furthermore, the administration of the dietary supplement did not result in any changes in the total cholesterol in the patients evaluated".

Women who were given capsules containing 2 grams of a combination of gamma linolenic acid, oleic acid, linoleic acid, other polyunsaturated acids and vitamin E reported significantly eased PMS symptoms at both 3 and 6 months after they began the treatment. Few adverse events were recorded and these were mild, insignificant and did not appear to be directly related to the medication.

Speaking about the results, Rocha Filho said, "The negative effect of PMS on a woman's routine activities and quality of life may be significant, in addition to the repercussions on economic costs resulting predominantly from a reduction in productivity. Essential oil capsules can now be said to show much promise as a treatment."

Source: BioMed Central

Related Videos
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
Rahul Aggarwal, MD | Credit: LinkedIn
Brendon Neuen, MBBS, PhD | Credit: X.com
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Atul Malhotra, MD | Credit: Kyle Dykes; UC San Diego Health
Optimizing Diabetes Therapies with New Classifications
Should We Reclassify Diabetes Subtypes?
Roger S. McIntyre, MD: GLP-1 Agonists for Psychiatry?
© 2024 MJH Life Sciences

All rights reserved.